Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4ZCY0)

• Drug Name: DSP-0337 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM4ZCY0

Molecule-Related Drug Atlas

Drug(s) Targeting Signal transducer and activator of transcription 3 (STAT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acitretin	DM8BKU9	Psoriasis vulgaris	EA90	Approved	[3]
Napabucasin	DMDZ6Q3	Colorectal cancer	2B91.Z	Phase 3	[4]
Golotimod	DMKZN3A	Immune System disease	4A01-4B41	Phase 2	[5]
NT219	DMOYS1N	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
WP-1066	DMUGHWR	Recurrent glioblastoma	2A00.00	Phase 1/2	[4]
Atiprimod	DM84YEC	Multiple myeloma	2A83	Phase 1/2	[7]
OPB-31121	DM6VGO3	Hepatocellular carcinoma	2C12.02	Phase 1/2	[8]
IMX-110	DMNHZS4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
GLG-801	DMY1CP9	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[4]
OPB-51602	DM760FA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Signal transducer and activator of transcription 3 (STAT3)	TTH8FZW	STAT3_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03416816) A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile. U.S. National Institutes of Health.
• [2] Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289.
• [3] Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] National Cancer Institute Drug Dictionary (drug id 617379).
• [6] Clinical pipeline report, company report or official report of Purple Biotech.
• [7] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [8] OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52.
• [9] Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005.